<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482599</url>
  </required_header>
  <id_info>
    <org_study_id>P05948</org_study_id>
    <secondary_id>19.4.304</secondary_id>
    <nct_id>NCT00482599</nct_id>
  </id_info>
  <brief_title>Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Parallel Group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and pharmacokinetics of Org 25969 in
      subjects with normal or impaired renal function and to evaluate the safety of Org 25969 in
      subjects with impaired renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2005</start_date>
  <completion_date type="Actual">April 13, 2006</completion_date>
  <primary_completion_date type="Actual">April 13, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from start administration of Org 25969 to recovery T4/T1 ratio to 0.9</measure>
    <time_frame>After surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start administration of Org 25969 to recovery T4/T1 ratio to 0.7 and 0.8</measure>
    <time_frame>After surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Anesthesia, General</condition>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Org 25969 given to subjects with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Impaired renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Org 25969 given to subjects with impaired renal function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients</description>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_label>Impaired renal function</arm_group_label>
    <other_name>Org 25969</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class 1 - 3 for renally impaired patients, ASA class 1-2 for control group

          -  Age at least 18 years

          -  Scheduled for general anesthesia without further need for muscle relaxation other than
             one single dose of 0.6 mg.kg-1 rocuronium

          -  Scheduled for surgical procedures in the supine position

          -  Written informed consent

          -  Creatinine clearance (CLCR) &lt; 30 mL/min for renally impaired group, CLCR = 80 mL/min
             for control group

        Exclusion Criteria:

          -  Known or suspected neuromuscular disorders impairing NMB

          -  Known or suspected (family) history of malignant hyperthermia

          -  Known or suspected allergy to narcotics, muscle relaxants or other medication used
             during general anesthesia

          -  Use of medication known to interfere with NMBA based on the dose and the time of
             administration, such as antibiotics, anticonvulsants and Mg2+

          -  Pregnancy

          -  Childbearing potential without using any of the following methods of birth control:
             condom or diaphragm with spermicide, vasectomized partner ( &gt; 6 months), intrauterine
             device, abstinence

          -  Breast-feeding

          -  Prior participation in any trial with Org 25969

          -  Participation in another clinical trial, not pre-approved by NV Organon, within 30
             days of entering into trial 19.4.304, or for the UK only: Participation in another
             clinical trial, within 30 days of entering into trial 19.4.304.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

